跳至主要内容
临床试验/JPRN-UMIN000019249
JPRN-UMIN000019249已完成未知

Investigation of clinical efficacy of Qing-Dai for patients with crohn's disease who have the loss of responsiveness for anti-TNF agents - clinical efficacy of Qing-Dai for patients with crohn's disease

Division of Gastroenterology and Hepatology, School of Medicine, Keio University0 个研究点目标入组 10 人开始时间: 2015年10月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1 Patients' CDAI was more than 450 or less than 150 at the entry 2 The patients were not treated with infliximab within 7 weeks. The patients were not treated with adalimumab within 10 days. 3 The presence of abdominal abscess 4 Patients had colitis-associated dysplasia. 5 Patients had symptomatic intestinal stenosis 6 Patients had pouch or stoma. 7 Patients have the history of side effect or allergy of Chinese herbal medicine. 8 Patients have serious infections. 9 Patients have serious heart disease 10 Serum creatinine is more than 2.0mg/dL 11 Total bilirubin is more than 2.0mg/dL or AST/ALT is more than 50IU/L 12 Patients have history of malignant diseases 13 Patients have obvious psychological disorders 14 Patients are pregnant or patients wish to conceive. 15 Changing the dose/addition/reduction of medication for CD within 12 weeks before the commencement of the study was not allowed. 16 Investigators regard the patients as the inappropriate person to enroll this clinical trial.

研究者

发起方
Division of Gastroenterology and Hepatology, School of Medicine, Keio University

相似试验